Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains

被引：28

作者：

Faulkner, Nikhil ^{[1
,2
]}

Ng, Kevin W. ^{[1
]}

Wu, Mary Y. ^{[3
]}

Harvey, Ruth ^{[4
]}

Margaritis, Marios ^{[5
]}

Paraskevopoulou, Stavroula ^{[5
]}

Houlihan, Catherine ^{[5
,6
]}

Hussain, Saira ^{[4
,7
]}

Greco, Maria ^{[7
]}

Bolland, William ^{[1
]}

Warchal, Scott ^{[3
]}

Heaney, Judith ^{[5
]}

Rickman, Hannah ^{[5
]}

Spyer, Moria ^{[5
,8
]}

Frampton, Daniel ^{[6
]}

Byott, Matthew ^{[5
]}

de Oliveira, Tulio ^{[9
,10
,11
,12
]}

Sigal, Alex ^{[9
,13
,14
]}

Kjaer, Svend ^{[15
]}

Swanton, Charles ^{[16
]}

Gandhi, Sonia ^{[17
]}

Beale, Rupert ^{[18
]}

Gamblin, Steve J. ^{[19
]}

McCauley, John W. ^{[4
]}

Daniels, Rodney Stuart ^{[4
]}

Howell, Michael ^{[3
]}

Bauer, David ^{[7
]}

Nastouli, Eleni ^{[1
,5
,8
]}

Kassiotis, George ^{[1
,20
]}

机构：

[1] Retroviral Immunol, London, England

[2] Imperial Coll London, Natl Heart & Lung Inst, London, England

[3] High Throughput Screening STP, London, England

[4] Worldwide Influenza Ctr, London, England

[5] UCLH NHS Trust, Adv Pathogen Diagnost Unit, London, England

[6] Div Infect & Immun, London, England

[7] RNA Virus Replicat Lab, London, England

[8] Dept Populat Policy & Practice, London, England

[9] Univ KwaZulu Natal, Sch Lab Med & Med Sci, Durban, South Africa

[10] KwaZulu Natal Res Innovat & Sequencing Platform, Durban, South Africa

[11] Ctr AIDS Programme Res South Africa, Durban, South Africa

[12] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA

[13] Africa Hlth Res Inst, Durban, South Africa

[14] Max Planck Inst Infect Biol, Berlin, Germany

[15] Struct Biol STP, London, England

[16] Canc Evolut & Genome Instabil Lab, London, England

[17] Neurodegradat Biol Lab, London, England

[18] Cell Biol Infect Lab, London, England

[19] Francis Crick Inst, Struct Biol Dis Proc Lab, London, England

[20] Imperial Coll London, Dept Infect Dis, St Marys Hosp, London, England

来源：

ELIFE | 2021年 / 10卷

关键词：

VARIANT; LONDON;

D O I：

10.7554/eLife.69317

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Background: The degree of heterotypic immunity induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains is a major determinant of the spread of emerging variants and the success of vaccination campaigns, but remains incompletely understood. Methods: We examined the immunogenicity of SARS-CoV-2 variant B.1.1.7 (Alpha) that arose in the United Kingdom and spread globally. We determined titres of spike glycoprotein-binding antibodies and authentic virus neutralising antibodies induced by B.1.1.7 infection to infer homotypic and heterotypic immunity. Results: Antibodies elicited by B.1.1.7 infection exhibited significantly reduced recognition and neutralisation of parental strains or of the South Africa variant B.1.351 (Beta) than of the infecting variant. The drop in cross-reactivity was significantly more pronounced following B.1.1.7 than parental strain infection. Conclusions: The results indicate that heterotypic immunity induced by SARS-CoV-2 variants is asymmetric.

引用

页数：12

共 27 条

[1] Aitken J, 2020, NAT BIOTECHNOL, V38, P927, DOI 10.1038/s41587-020-0588-y
[2] Brown J, 2021, BLACK UTOPIAS, P1
[3] Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Cele, Sandile
Gazy, Inbal
Jackson, Laurelle
Hwa, Shi-Hsia
Tegally, Houriiyah
Lustig, Gila
Giandhari, Jennifer
Pillay, Sureshnee
Wilkinson, Eduan
Naidoo, Yeshnee
Karim, Farina
Ganga, Yashica
Khan, Khadija
Bernstein, Mallory
Balazs, Alejandro B.
Gosnell, Bernadett, I
Hanekom, Willem
Moosa, Mahomed-Yunus S.
Lessells, Richard J.
de Oliveira, Tulio
Sigal, Alex
[J]. NATURE, 2021, 593 (7857) : 142 - +
[4] Diamond Michael, 2021, Res Sq, DOI 10.21203/rs.3.rs-228079/v1
[5] Edara Venkata Viswanadh, 2021, bioRxiv, DOI 10.1101/2021.02.20.432046
[6] Data, disease and diplomacy: GISAID's innovative contribution to global health
Elbe, Stefan
Buckland-Merrett, Gemma
[J]. GLOBAL CHALLENGES, 2017, 1 (01) : 33 - 46
[7] Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Emary, Katherine R. W.
Golubchik, Tanya
Aley, Parvinder K.
Ariani, Cristina, V
Angus, Brian
Bibi, Sagida
Blane, Beth
Bonsall, David
Cicconi, Paola
Charlton, Sue
Clutterbuck, Elizabeth A.
Collins, Andrea M.
Cox, Tony
Darton, Thomas C.
Dold, Christina
Douglas, Alexander D.
Duncan, Christopher J. A.
Ewer, Katie J.
Flaxman, Amy L.
Faust, Saul N.
Ferreira, Daniela M.
Feng, Shuo
Finn, Adam
Folegatti, Pedro M.
Fuskova, Michelle
Galiza, Eva
Goodman, Anna L.
Green, Catherine M.
Green, Christopher A.
Greenland, Melanie
Hallis, Bassam
Heath, Paul T.
Hay, Jodie
Hill, Helen C.
Jenkin, Daniel
Kerridge, Simon
Lazarus, Rajeka
Libri, Vincenzo
Lillie, Patrick J.
Ludden, Catherine
Marchevsky, Natalie G.
Minassian, Angela M.
McGregor, Alastair C.
Mujadidi, Yama F.
Phillips, Daniel J.
Plested, Emma
Pollock, Katrina M.
Robinson, Hannah
Smith, Andrew
Song, Rinn
[J]. LANCET, 2021, 397 (10282) : 1351 - 1362
[8] Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study
Frampton, Dan
Rampling, Tommy
Cross, Aidan
Bailey, Heather
Heaney, Judith
Byott, Matthew
Scott, Rebecca
Sconza, Rebecca
Price, Joseph
Margaritis, Marios
Bergstrom, Malin
Spyer, Moira J.
Miralhes, Patricia B.
Grant, Paul
Kirk, Stuart
Valerio, Chris
Mangera, Zaheer
Prabhahar, Thaventhran
Moreno-Cuesta, Jeronimo
Arulkumaran, Nish
Singer, Mervyn
Shin, Gee Yen
Sanchez, Emilie
Paraskevopoulou, Stavroula M.
Pillay, Deenan
McKendry, Rachel A.
Mirfenderesky, Mariyam
Houlihan, Catherine F.
Nastouli, Eleni
[J]. LANCET INFECTIOUS DISEASES, 2021, 21 (09) : 1246 - 1256
[9] Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]
[10] Grant P R., 2020, BioRxiv, V19, P2, DOI DOI 10.1101/2020.04.06.028316

← 1 2 3 →